HUJ is the latest site for Evotec's Bridge drug discovery model, which supports pre-spinout academic research to advance promising drug candidates.
Yissum, the tech transfer company of Hebrew University of Jerusalem (HUJ), yesterday joined forces with drug discovery firm Evotec to launch Lab555, the latest iteration of the latter’s academic commercialisation bridge model.
Evotec and Yissum are joined in the initiative by Integra Holdings, an investment firm focused on HUJ life sciences spinouts. The financial terms of the collaboration were not disclosed.
Lab555 will attempt to accelerate early-stage Hebrew University drug discovery research, combining Integra’s knowledge of the HUJ ecosystem with Evotec’s industry-scale development resources.
The partners expect to sustain multiple HUJ programs as they work towards proving concepts to the extent that the creation of new spinouts is justified.
Lab555 is the latest addition to Evotec’s international network of early-stage academic collaborations, branded Bridge as shorthand for Biomedical Research, Innovation and Development Generation Efficiency.
Evotec’s other academic initiatives include partnerships with Harvard University, Canada’s…
